Stock INBX INHIBRX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Inhibrx, Inc.

Equities

INBX

US45720L1070

Market Closed - Nasdaq
Other stock markets
 03:58:00 2024-05-30 am EDT 		5-day change 1st Jan Change
34.11 USD +0.09% Intraday chart for Inhibrx, Inc. -0.70% -10.24%
May. 31 Inhibrx, Inc.(NasdaqGM:INBX) dropped from S&P Biotechnology Select Industry Index CI
May. 31 Inhibrx, Inc.(NasdaqGM:INBX) dropped from S&P Global BMI Index CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Inhibrx, Inc.(NasdaqGM:INBX) dropped from S&P Biotechnology Select Industry Index
Inhibrx, Inc.(NasdaqGM:INBX) dropped from S&P Global BMI Index
Inhibrx, Inc.(NasdaqGM:INBX) dropped from S&P TMI Index
Sanofi Closes Purchase of US Biotech Company Inhibrx
Sanofi : finalisation de l'acquisition d'Inhibrx
Inhibrx, Inc. completed the Spin-Off of 92% stake in Inhibrx Biosciences, Inc..
Aventis Inc. completed the acquisition of Inhibrx, Inc. from a group of shareholders.
Inhibrx, Inc.(NasdaqGM:INBX) dropped from NASDAQ Biotechnology Index
Inhibrx Shareholders Approve Sale of INBRX-101 Assets to Sanofi
Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi
Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off
Inhibrx : Reports First Quarter 2024 Financial Results and Recent Corporate Highlights - Form 8-K
Inhibrx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX
Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger
TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger - HMST, FREE, EVBG, INBX
Inhibrx Shares Fall After Q4 Net Loss Widens
Earnings Flash (INBX) INHIBRX Reports Q4 Revenue $1.6M
Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results
Inhibrx, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. INBX Stock
  4. News Inhibrx, Inc.
  5. Other languages